Literature DB >> 9707160

Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint.

J A den Boer1.   

Abstract

Antidepressants and high-potency benzodiazepines have been used to treat patients with panic disorder. This review considers the efficacy of these treatments in reducing panic attack frequency and in addition considers their ability to attenuate global anxiety, depressive symptomatology, agoraphobic avoidance, and overall impairment. An extensive database is available for the tricyclic antidepressants imipramine and clomipramine, the serotonin selective reuptake inhibitor paroxetine, and the benzodiazepine alprazolam. The antidepressants are more effective than the benzodiazepines in reducing associated depressive symptomatology and are at least as effective for improving anxiety, agoraphobia, and overall impairment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707160

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Panic disorder.

Authors:  M H Rapaport; C Barrett
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 2.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Dose-finding study of fluoxetine and venlafaxine for the treatment of self-injurious and stereotypic behavior in rhesus macaques (Macaca mulatta).

Authors:  M Babette Fontenot; Mandi W Musso; Robert M McFatter; George M Anderson
Journal:  J Am Assoc Lab Anim Sci       Date:  2009-03       Impact factor: 1.232

4.  Psychopharmacology of anxiety disorders.

Authors:  Giovanni B Cassano; Nicolò Baldini Rossi; Stefano Pini
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

5.  Pharmacological management of panic disorder.

Authors:  Carlo Marchesi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.